Alvotech (ALVO) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ALVO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Alvotech ( ALVO ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Robert Wessman - Founder & Executive Chairman Balaji Prasad - Chief Strategy Officer Conference Call Participants …

Alvotech NASDAQ: ALVO expects its full-year revenue and adjusted earnings to land near the lower end of its guidance range, as the biosimilar maker works to increase deliveries following a manufacturing slowdown.…

Alvotech (ALVO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.…

REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicine…

Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a significant second-half …

REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced t…

REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, t…

ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.…

Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio…

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)…

Shares of Alvotech (NASDAQ: ALVO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rate…

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing capacity and support grow…

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites…

Alvotech (NASDAQ: ALVO - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rec…

Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength…

REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that…

REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced th…

U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Monday.…

REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, toda…

Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with B…

Alvotech (ALVO) Q2 2026 Earnings Call Transcript…

Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue an…

Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

